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Abstract The membrane bound guanylyl cyclase (GC) photo-
receptor membrane GC1 (ROS-GC1) of photoreceptor cells
synthesizes cGMP, the intracellular transmitter of vertebrate
phototransduction. The activity of ROS-GC1 is controlled by
small Ca2-binding proteins, named GC-activating proteins
(GCAPs). We identified and characterized two short regulatory
regions (M445^L456 and L503^I522) in the juxtamembrane
domain (JMD) of ROS-GC1 by peptide competition and
mutagenesis studies. Both regions are critical for the activation
of ROS-GC1 by GCAP-1.
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1. Introduction
In vertebrate photoreceptor cells, light induces the ampli¢ed
hydrolysis of cGMP, which leads to the closure of cyclic nu-
cleotide-gated (CNG) channels (for reviews, [1^4]). The clo-
sure of CNG channels prevents the in£ux of Ca2 into the
outer segment of the photoreceptor cell. Since Ca2 is contin-
uously extruded via a Na/Ca,K-exchanger, the cytoplasmic
[Ca2] decreases after illumination from 500 to 50 nM.
Changes in cytoplasmic [Ca2] are sensed by Ca2-binding
proteins like calmodulin, recoverin and the guanylyl cyclase
(GC)-activating proteins (GCAPs). GCAPs activate a mem-
brane bound GC below 200 nM free [Ca2] to enhance the
resynthesis of cGMP [5^11]. In vertebrate photoreceptor cells,
two isoforms of a membrane bound GC are found [12^19].
They are synonymously termed rod outer segments GC1
(ROS-GC1) and ROS-GC2 or GC-E and GC-F, respectively.
ROS-GCs serve a key function in phototransduction, since
they synthesize the intracellular messenger cGMP under the
control of a negative Ca2 feedback. Since changes in cyto-
plasmic [Ca2] control the light sensitivity of photoreceptor
cells, the regulation of ROS-GCs by Ca2 and GCAPs is a
key mechanism of light adaptation (for reviews, [4,20^22]).
The molecular control mechanisms by which GCAPs regu-
late the activity of ROS-GCs on the intracellular side are not
understood in detail [9,23^25]. Previous experiments have in-
dicated that two isoforms of GCAP, GCAP-1 and GCAP-2,
are associated with ROS-GCs independent of [Ca2] [7,9,26^
28]. Therefore, it was proposed that activation of ROS-GCs is
triggered by a Ca2-dependent conformational switch in a
stable ROS-GC/GCAP complex. As a ¢rst step to understand
the activation mechanism at a molecular level, we sought to
identify regions in ROS-GC1 that participate in target recog-
nition and/or regulation by GCAP-1. Within the intracellular
domain of ROS-GC1, the juxtamembrane domain (JMD) and
the kinase homology domain (KHD) are necessary constitu-
ents for activation by GCAP-1 [9]. Deletion of the JMD and
of the KHD of ROS-GC1 (S447^I730) results in loss of
GCAP-1 sensitivity.
It was the aim of our study to identify short sequence mo-
tifs in ROS-GC1 that are critical for activation by GCAP-1.
Two hypothetical regulatory domains in the JMD were iden-
ti¢ed by using a synthetic oligopeptide library and by charac-
terizing corresponding mutants.
2. Materials and methods
2.1. Synthesis of oligopeptide library
Peptides encompassing the JMD (R437^G552; Fig. 1A) of bovine
photoreceptor GC ROS-GC1 were synthesized with a multipin pep-
tide synthesis kit (Chiron Mimotopes) according to Schrem et al. [28].
Each peptide was 12 amino acids long and overlapped the preceding
one by 10 amino acids. Larger amounts of peptides #3a, #5, #34a
and #36 were synthesized and puri¢ed according to Zoche et al. [29].
2.2. Preparation of ROS
ROS were prepared from fresh bovine retinae as described previ-
ously [10,12]. The predominant GC in our ROS preparation is ROS-
GC1 (L. Molday, B. Molday and K.-W. Koch, unpublished observa-
tion).
2.3. GC assay
The activity of ROS-GC1 was determined by either a high perform-
ance liquid chromatography (HPLC) assay using a nucleotide separa-
tion and quantitation system [10,12] or by a radioimmuno assay [30].
Peptide competition experiments were carried out as previously de-
scribed [28] in the presence of 0.1 mM ATP to increase ROS-GC1
activity independent of GCAP-1 [12].
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2.4. Heterologous expression and puri¢cation of GCAP-1
Recombinant GCAP-1 was heterologously expressed in Escherichia
coli and puri¢ed from inclusion bodies exactly as described previously
[28].
2.5. Mutagenesis and expression
Four ROS-GC1 deletion mutants, v1 (deleted amino acids M445^
L456), v2 (deleted amino acids R489^I522), v3 (deleted amino acids
D507^R518) and K3 (deleted amino acids S447^I730), were con-
structed. The numbering corresponds to the mature ROS-GC1 protein
[15]. Construction of the K3 mutant is described in [9]. The v1 mu-
tant was generated by ‘looping-out’ nucleotides 1552^1587 in ROS-
GC1 cDNA. To construct the v2 and v3 mutants, two HpaI restric-
tion sites were introduced into ROS-GC1 cDNA. For the former
mutant, the sites were at nucleotide positions 1683 and 1785 and
for the latter, they were at 1737 and 1774. The desired fragments
were excised and the remaining parts re-ligated. All constructs were
sequenced to con¢rm their identities. The mutated cDNAs were
cloned into KpnI/XbaI sites of the pcDNA vector for expression in
mammalian cells. ROS-GC1 and mutants were expressed in COS cells
as previously described [30].
3. Results
3.1. Screening of a ROS-GC1 oligopeptide library
Photoreceptor speci¢c membrane bound ROS-GC1 is acti-
vated by GCAPs through its intracellular domain, a process
that is di¡erent from the activation of hormone receptor GCs
by extracellular ligands. A sequence comparison of ROS-GC1
with ROS-GC2 and the hormone receptor atrial natriuretic
factor receptor GC (GC-A) revealed that the JMD (R437^
G552; JMD in Fig. 1A) is highly homologous in ROS-GC1
and ROS-GC2, but is completely di¡erent in GC-A and ROS-
GC1 (Fig. 1B,C). We reasoned that the JMD contains regions
that are speci¢c for the regulation by GCAP-1. In order to
identify critical amino acid stretches within the JMD, we syn-
thesized a peptide library of overlapping 12-mer oligopeptides
(Fig. 1A). Peptides were screened for their ability to inhibit
GCAP-1-mediated activation of ROS-GC1 in puri¢ed ROS.
Inhibitory e¡ects of peptides (0.3 mM) on ROS-GC1 activ-
ity were tested both at 24 WM [Ca2] (2 mM CaEGTA) and at
1 nM free [Ca2] (2 mM EGTA). This allowed us to di¡er-
entiate between peptide e¡ects on the basal state of ROS-GC1
(at high [Ca2]) and on the activated state of ROS-GC1 (at
low [Ca2]). Two small regions represented by peptides #1^5
(except #4) and #35/36 showed a signi¢cant inhibitory e¡ect
on the ROS-GC1 activity at low [Ca2] (Fig. 2A). ROS-GC1
activity at high [Ca2] was also diminished by #35/36 and, to
a lesser extent, by #2 and #5 (Fig. 2B). It was puzzling that
peptide #4 had no e¡ect, although peptides #3 and #5 were
the most e¡ective. A HPLC analysis of #4 showed an inho-
mogenous product after synthesis.
3.2. Peptide competition studies
In order to con¢rm the results of the screening, we tested
the inhibitory peptides in titration series at high and low
[Ca2]. We also included extended versions of peptides #5
and #35 (Fig. 1, peptides #3a and #34a). Peptides #5 and
#34a were the most e¡ective and inhibited ROS-GC1 in a
concentration-dependent way (Fig. 3A,B). Half-maximal in-
hibition was observed at concentrations (IC50) of 100 WM
(#5, without Ca2), 250 WM (#34a, without Ca2), 260 WM
(#5, with Ca2) and 150 WM (#34a, with Ca2). Peptide #5
inhibited ROS-GC1 more e¡ectively at low [Ca2] than at
high [Ca2], whereas #34a was slightly more e⁄cient at high
[Ca2]. A peptide representing the region K762^L773 of the
dimerization domain did not in£uence the ROS-GC1 activity
at 0.3 mM and was used as a control in the titration set
experiment in Fig. 3A,B. It was much less e¡ective than pep-
tides #5 and #34a.
The inhibitory e¡ects of peptides #5, #34a and #36 were
Fig. 1. A: Domain structure of bovine ROS-GC1. The location of
overlapping peptides and their corresponding numbers are indicated
(e.g. peptides #1^53 encompass R437^G552). The abbreviations are:
LS, leader sequence in the unprocessed protein; ECD, extracellular
(intradiscal) domain; TM, transmembrane domain; KHD, kinase
homology domain; DD, hypothetical dimerization domain; CCD,
cyclase catalytic domain; C-T, C-terminus. Positions of peptides
#3a and #34a are indicated. Positions of #5 and #36 are typed in
bold letters and are underlined. Comparison of amino acid sequen-
ces of bovine ROS-GC1 [15] with the corresponding parts of bovine
(bt) ROS-GC2 [18] (B) and human (hs) GC-A (GenBank accession
number NM000906) (C) illustrated in a dot blot matrix analysis.
Analysis was performed with the program PDOTPLOT, version
3.13 (Dr W. Bo«nigk, IBI-1, FZ-Ju«lich) using the following parame-
ter: matrix MDM [36], window 12 amino acids, cuto¡ score 300.
Only the cytoplasmic parts of the proteins are compared. A high de-
gree of sequence homology is seen as a diagonal black line.
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reversible. For example, ROS containing ROS-GC1 and en-
dogenous GCAP-1 were incubated at low [Ca2] with either
320 WM #5 or 1 mM #36, which led to an inhibition of 80^
90% compared to the control. Addition of 20 WM recombi-
nant GCAP-1 to the same ROS suspension completely re-
lieved the inhibition (not shown).
The results of the screening approach and the competition
studies suggest that peptides #1^5 interfered mainly with the
activated state of ROS-GC1 and that peptide #34a interfered
with the basal and activated state of ROS-GC1. We conclude
that #5 and #34a represent important regulatory sites within
the JMD of ROS-GC1.
3.3. Characterization of ROS-GC1 mutants
We further focused on these two regions to investigate their
role in regulating ROS-GC1 activity. The mutants v1 (M445^
L456, corresponding to peptide #5), v2 (R489^I522, corre-
sponding to peptide #34a plus £anking regions) and v3
(D507^R518, corresponding to peptide #36) were constructed.
The expression level of all mutants in COS and HEK293 cells
was similar to the wild-type as assessed by Western blotting
(data not shown). All three deletion mutants showed a greatly
decreased basal activity compared to the wild-type in COS
cells. In contrast, deletion of a larger intracellular domain
encompassing the whole KHD amino acids S447^I730 (desig-
nated K3) does not lead to a reduction in basal ROS-GC1
activity (Fig. 4; [9]). GCAP-1 failed to activate all four mu-
tants, whereas GC activity of the wild-type was stimulated 4^
5-fold by addition of GCAP-1 above saturation (2 WM) (Fig.
5A). When expressed in HEK cells, the v1 mutant was slightly
stimulated at higher concentrations of GCAP-1 (s 5 WM).
However, basal activity and activation by GCAP-1 were
also largely reduced when compared to the wild-type. To con-
¢rm the structural integrity of the mutants, we tested whether
Fig. 2. Percentage inhibition of GCAP-1-dependent activation of
ROS-GC1 at 1 nM [Ca2] (i.e. in the presence of 2 mM EGTA)
(A) and 24 WM [Ca2] (B). Peptides at 0.5 mg/ml (0.3 mM) were
added to a suspension of bovine ROS and incubated at the indi-
cated free [Ca2]. Data represent the mean þ S.D. of 2^4 measure-
ments. Dotted lines indicate the S.D. of the overall mean and serve
as threshold criterion.
Fig. 3. Inhibition of ROS-GC1 activity in whole ROS as a function
of the peptide concentration (F #5, R #34a, a control peptide).
ROS-GC1 activity was determined at 1 nM [Ca2] (A) and at
24 WM [Ca2] (B). All data are the mean of three determina-
tions þ S.D. Absolute values for GC activity were normalized to val-
ues obtained without peptides.
Fig. 4. Activity of heterologously expressed ROS-GC1 mutants in
comparison to the wild-type. Mutants and wild-type were expressed
in COS cells and membranes were assayed for basal GC activity at
10 WM [Ca2]. K3 denotes a mutant that lacks the JMD and the
KHD. v1, v2 and v3 denote mutants that lack the regions repre-
sented by peptides #5, #34a and #36 (see text).
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ROS-GC1 mutants did respond to another EF-hand Ca2-
binding protein S100L (also termed CD-GCAP). S100L is
known to activate ROS-GC1 at micromolar [Ca2] [31,32].
It interacts with a di¡erent region than GCAP-1 [33]. S100L
was able to activate all mutants to nearly the same relative
extent as the wild-type (Fig. 5B). We conclude from these
experiments that the ROS-GC1 mutants did not su¡er from
a general impairment of their function. Instead, they had se-
lectively lost the ability to respond to GCAP-1.
4. Discussion
Our analysis of GCAP-1/ROS-GC1 interaction has revealed
that two regions represented by peptides #5 and #34a are
critical for activation of ROS-GC1 by GCAP-1. The two pep-
tides acted di¡erently on the Ca2-dependent activation of
ROS-GC1 (Fig. 2 and 3). Since peptide #5 inhibited more
e¡ectively the activated state of ROS-GC1, we conclude that
this region represents a GCAP-1-dependent transducer motif
of ROS-GC1. The motif is necessary to cause Ca2-dependent
activation of the cyclase catalytic domain.
One position in region #34a is of particular interest. Pa-
tients who su¡er from the retinal disease named Leber’s con-
genital amaurosis have a mutated form of ROS-GC1 [34], i.e.
the phenylalanine in position 514 is mutated to a serine. A
recent paper by Duda et al. [30] showed that ROS-GC1 with a
F514S mutation has a decreased basal activity and has com-
pletely lost the sensitivity to GCAP-1. The mutant, however,
responds normally to S100L. These results are in strong sup-
port of our ¢nding that the sequence covered by peptide #34a
represents a main regulatory site for GCAP-1.
Both regions are located in the JMD more than 300 amino
acids upstream from the catalytic domain. Recently, Sokal et
al. [35] identi¢ed a peptide in the catalytic domain of ROS-
GC1 as a GCAP-1-binding site. Preliminary results from our
laboratories indicated that region #34a represents a second
interaction site for GCAP-1 (in preparation). We conclude
that GCAP-1 interacts with more than one site in ROS-
GC1. Peptide #34a and the peptide of Sokal et al. [35] are
at remote distances in the primary structure within the cyclase
molecule. We hypothesize that in the tertiary structure of
ROS-GC1, the cyclase catalytic domain and the JMD form
a multipoint attachment site for GCAP-1.
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